Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023

  • Gogichadze, Nino
  • Sagrera, Arnau
  • Vicente, José Ángel
  • Millet, Joan-Pau
  • López Seguí, Francesc, 1991-
  • Vilaplana Prieto, Cristina
Includes supplementary materials for the online appendix., Background: In countries with a low TB incidence (≤ 10 cases/100,000 population), active pulmonary tuberculosis (PTB) mostly affects vulnerable populations with limited access to healthcare. Thus, passive case-finding systems may not be successful in detecting and treating cases and preventing further transmission. Active and cost-effective search strategies can overcome this problem. Aim: We aimed to review the evidence on the cost-effectiveness (C-E) of active PTB screening programmes among high-risk populations in low TB incidence countries. Methods: We performed a systematic literature search covering 2008–2023 on PubMed, Embase, Center for Reviews and Dissemination, including Database of Abstracts of Reviews of Effects (DARE), National Health Services Economic Evaluation Database (NHS EED), Global Index Medicus and Cochrane Central Register of Controlled Trials (CENTRAL). Results: We retrieved 6,318 articles and included nine in this review. All included studies had an active case-finding approach and used chest X-ray, tuberculin skin test, interferon-gamma release assay and a symptoms questionnaire for screening. The results indicate that screening immigrants from countries with a TB incidence > 40 cases per 100,000 population and other vulnerable populations as individuals from isolated communities, people experiencing homelessness, those accessing drug treatment services and contacts, is cost-effective in low-incidence countries. Conclusion: In low-incidence countries, targeting high-risk groups is C-E. However, due to the data heterogenicity, we were unable to compare C-E. Harmonisation of the methods for C-E analysis is needed and would facilitate comparisons. To outline comprehensive screening and its subsequent C-E analysis, researchers should consider multiple factors influencing screening methods and outcomes., This work was supported by the Catalan Government via 2021 SGR-00920 and received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number. 847762.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings

  • Romero Tamarit, Arantxa
  • Munar García, María
  • Domínguez Álvarez, Marisol
  • Jové, Neus
  • Vilaplana Massaguer, Cristina
Purpose: This study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution. Methods: People with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed. Results: The study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months. Conclusions: IP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB., This work was supported by the Catalan Government via 2017 SGR 500, 2021 SGR 00920; the Spanish Government-FEDER Funds via CPII18/00031, PI20/01424, PI22/00766, the CIBER Enfermedades Respiratorias (CB06/06/0031); and the Spanish Society of Pneumology and Thoracic Surgery, under Grant No. 169-2022. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 847762.
IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • de Homdedeu, Miquel
  • Sanchez-Moral, Lidia
  • Violán, Concepció
  • Ràfols, Neus
  • Ouchi, Dan
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodríguez-Cortés, Alhelí
  • Arch-Sisquella, Marta
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Izquierdo-Useros, Nuria
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi
  • Segalés, Joaquim
  • Vilaplana, Cristina
  • Torán-Monserrat, Pere
  • Morros, Rosa
  • Monfà, Ramon
  • Sarrias, Maria-Rosa
  • Cardona, Pere-Joan
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days., The MANRECOVID19 clinical trial has been sponsored by the Reig Jofre Group. This research was funded by the Consorcio Centro de Investigación Biomédica en Red (CIBERES and CIBEREHD) and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847762. MDH is supported by a Margarita Salas grant from NextGenerationEU. LS-M is supported by Juan de la Cierva fellowship (FJC2019-041213-I). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118), and institutional funding from Grifols, Pharma Mar, HIPRA, Amassence, and Palobiofarma. The Innate Immunity lab and the UTE are accredited by the Catalan Agency for Management of University and Research Grants (2017-SGR-490/2021-SGR-01186, 2021-SGR-00931, and 2017-SGR-500/2021 SGR 00920). IGTP is a member of the CERCA network of institutes supported by the Health Department of the Government of Catalonia., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries: a systematic review, 2008 to 2023

  • Gogichadze, Nino
  • Sagrera, Arnau
  • Vicente, José Ángel
  • Millet, Joan-Pau
  • López Seguí, Francesc, 1991-
  • Vilaplana Prieto, Cristina
Includes supplementary materials for the online appendix., Background: In countries with a low TB incidence (≤ 10 cases/100,000 population), active pulmonary tuberculosis (PTB) mostly affects vulnerable populations with limited access to healthcare. Thus, passive case-finding systems may not be successful in detecting and treating cases and preventing further transmission. Active and cost-effective search strategies can overcome this problem. Aim: We aimed to review the evidence on the cost-effectiveness (C-E) of active PTB screening programmes among high-risk populations in low TB incidence countries. Methods: We performed a systematic literature search covering 2008–2023 on PubMed, Embase, Center for Reviews and Dissemination, including Database of Abstracts of Reviews of Effects (DARE), National Health Services Economic Evaluation Database (NHS EED), Global Index Medicus and Cochrane Central Register of Controlled Trials (CENTRAL). Results: We retrieved 6,318 articles and included nine in this review. All included studies had an active case-finding approach and used chest X-ray, tuberculin skin test, interferon-gamma release assay and a symptoms questionnaire for screening. The results indicate that screening immigrants from countries with a TB incidence > 40 cases per 100,000 population and other vulnerable populations as individuals from isolated communities, people experiencing homelessness, those accessing drug treatment services and contacts, is cost-effective in low-incidence countries. Conclusion: In low-incidence countries, targeting high-risk groups is C-E. However, due to the data heterogenicity, we were unable to compare C-E. Harmonisation of the methods for C-E analysis is needed and would facilitate comparisons. To outline comprehensive screening and its subsequent C-E analysis, researchers should consider multiple factors influencing screening methods and outcomes., This work was supported by the Catalan Government via 2021 SGR-00920 and received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement number. 847762.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings

  • Romero Tamarit, Arantxa
  • Munar García, María
  • Domínguez Álvarez, Marisol
  • Jové, Neus
  • Vilaplana Massaguer, Cristina
Purpose: This study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution. Methods: People with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed. Results: The study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months. Conclusions: IP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB., This work was supported by the Catalan Government via 2017 SGR 500, 2021 SGR 00920; the Spanish Government-FEDER Funds via CPII18/00031, PI20/01424, PI22/00766, the CIBER Enfermedades Respiratorias (CB06/06/0031); and the Spanish Society of Pneumology and Thoracic Surgery, under Grant No. 169-2022. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No. 847762.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Mycobacterium manresensis induces trained immunity in vitro

  • de Homdedeu, Miquel
  • Sanchez-Moral, Lidia
  • Violán, Concepció
  • Ràfols, Neus
  • Ouchi, Dan
  • Martín, Berta
  • Peinado, Miguel A.
  • Rodríguez-Cortés, Alhelí
  • Arch-Sisquella, Marta
  • Perez-Zsolt, Daniel
  • Muñoz Basagoiti, Jordana
  • Izquierdo-Useros, Nuria
  • Salvador, Betlem
  • Matllo, Joan
  • López-Serrano, Sergi
  • Segalés, Joaquim
  • Vilaplana, Cristina
  • Torán-Monserrat, Pere
  • Morros, Rosa
  • Monfà, Ramon
  • Sarrias, Maria-Rosa
  • Cardona, Pere-Joan
The COVID-19 pandemic posed a global health crisis, with new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants weakening vaccine-driven protection. Trained immunity could help tackle COVID-19 disease. Our objective was to analyze whether heat-killed Mycobacterium manresensis (hkMm), an environmental mycobacterium, induces trained immunity and confers protection against SARS-CoV-2 infection. To this end, THP-1 cells and primary monocytes were trained with hkMm. The increased secretion of tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1β, and IL-10, metabolic activity, and changes in epigenetic marks suggested hkMm-induced trained immunity in vitro. Healthcare workers at risk of SARS-CoV-2 infection were enrolled into the MANRECOVID19 clinical trial (NCT04452773) and were administered Nyaditum resae (NR, containing hkMm) or placebo. No significant differences in monocyte inflammatory responses or the incidence of SARS-CoV-2 infection were found between the groups, although NR modified the profile of circulating immune cell populations. Our results show that M. manresensis induces trained immunity in vitro but not in vivo when orally administered as NR daily for 14 days., The MANRECOVID19 clinical trial has been sponsored by the Reig Jofre Group. This research was funded by the Consorcio Centro de Investigación Biomédica en Red (CIBERES and CIBEREHD) and the European Union’s Horizon 2020 research and innovation programme under grant agreement No 847762. MDH is supported by a Margarita Salas grant from NextGenerationEU. LS-M is supported by Juan de la Cierva fellowship (FJC2019-041213-I). NI-U is supported by the Spanish Ministry of Science and Innovation (grant PID2020-117145RB-I00), EU HORIZON-HLTH-2021-CORONA-01 (grant 101046118), and institutional funding from Grifols, Pharma Mar, HIPRA, Amassence, and Palobiofarma. The Innate Immunity lab and the UTE are accredited by the Catalan Agency for Management of University and Research Grants (2017-SGR-490/2021-SGR-01186, 2021-SGR-00931, and 2017-SGR-500/2021 SGR 00920). IGTP is a member of the CERCA network of institutes supported by the Health Department of the Government of Catalonia., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A longitudinal prospective study of active tuberculosis in a Western Europe setting, insights and findings

  • Romero-Tamarit, Arantxa
  • Vallès, Xavier|||0000-0002-4445-1490
  • Munar-García, María
  • Espinosa-Pereiro, Juan|||0000-0002-7238-8337
  • Saborit, Núria
  • Tórtola Fernández, María Teresa|||0000-0002-9188-298X
  • Stojanovic, Zoran|||0000-0001-5082-0750
  • Roure, Silvia|||0000-0002-7982-0890
  • Antuori Torres, Adrián|||0000-0002-2782-3125
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Soriano-Arandes, Antoni|||0000-0001-9613-7228
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Espiau, María|||0000-0001-9697-7649
  • De Souza Galvão, Maria Luiza|||0000-0001-9703-989X
  • Jiménez, Ma. Ángeles
  • Noguera-Julian, Antoni|||0000-0001-7485-0583
  • Molina Romero, Israel|||0000-0001-6642-7515
  • Casas, Xavier|||0000-0002-3892-9697
  • Domínguez-Álvarez, Marisol
  • Jové, Neus
  • Gogichadze, Nino|||0000-0001-7014-1608
  • Fonseca, Kaori L.|||0000-0002-7048-9740
  • Arias, Lilibeth|||0000-0002-2469-8832
  • Millet, Joan Pau|||0000-0003-0200-2459
  • Sánchez Montalvá, Adrián|||0000-0002-2194-5447
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
This study investigates the potential of inflammatory parameters (IP), symptoms, and patient-related outcome measurements as biomarkers of severity and their ability to predict tuberculosis (TB) evolution. People with TB were included prospectively in the Stage-TB study conducted at five clinical sites in Barcelona (Spain) between April 2018 and December 2021. Data on demographics, epidemiology, clinical features, microbiology, and Sanit George Respiratory Questionnaire (SGRQ) and Kessler-10 as Health-Related Quality of Life (HRQoL) were collected at three time points during treatment. C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), neutrophil/lymphocyte, and monocyte/lymphocyte ratios (NLR and MLR), complement factors C3, C4, and cH50, clinical and microbiological data, and HRQoL questionnaires were assessed at baseline, 2 months, and 6 months. Their ability to predict sputum culture conversion (SCC) and symptom presence after 2 months of treatment was also analysed. The study included 81 adults and 13 children with TB. The CRP, ESR, NLR, and MLR values, as well as the presence of symptoms, decreased significantly over time in both groups. Higher IP levels at baseline were associated with greater bacillary load and persistent symptoms. Clinical severity at baseline predicted a delayed SCC. Kessler-10 improved during follow-up, but self-reported lung impairment (SGRQ) persisted in all individuals after 6 months. IP levels may indicate disease severity, and sustained high levels are linked to lower treatment efficacy. Baseline clinical severity is the best predictor of SCC. Implementing health strategies to evaluate lung function and mental health throughout the disease process may be crucial for individuals with TB. The online version contains supplementary material available at 10.1007/s15010-024-02184-2.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cost-effectiveness of active tuberculosis screening among high-risk populations in low tuberculosis incidence countries, a systematic review, 2008 to 2023

  • Gogichadze, Nino|||0000-0001-7014-1608
  • Sagrera, Arnau
  • Vicente, José Ángel
  • Millet, Joan Pau|||0000-0003-0200-2459
  • López-Seguí, Francesc
  • Vilaplana Massaguer, Cristina|||0000-0002-2808-7270
Background: In countries with a low TB incidence (≤ 10 cases/100,000 population), active pulmonary tuberculosis (PTB) mostly affects vulnerable populations with limited access to healthcare. Thus, passive case-finding systems may not be successful in detecting and treating cases and preventing further transmission. Active and cost-effective search strategies can overcome this problem. Aim: We aimed to review the evidence on the cost-effectiveness (C-E) of active PTB screening programmes among high-risk populations in low TB incidence countries. Methods: We performed a systematic literature search covering 2008-2023 on PubMed, Embase, Center for Reviews and Dissemination, including Database of Abstracts of Reviews of Effects (DARE), National Health Services Economic Evaluation Database (NHS EED), Global Index Medicus and Cochrane Central Register of Controlled Trials CENTRAL). Results: We retrieved 6,318 articles and included nine in this review. All included studies had an active case-finding approach and used chest X-ray, tuberculin skin test, interferon-gamma release assay and a symptoms questionnaire for screening. The results indicate that screening immigrants from countries with a TB incidence.